This report was first published by Endpoints News. To see the original version, click here
There’s been no end to the debate about whether US and European companies should have an open door to innovation and assets coming from China, or whether there should be regulatory or legislative barriers to protect the US’s competitive edge in a cornerstone industry.
Today on Post-Hoc Live at 12:30 p.m. ET, we’ll hear from one of the groups that’s pushing for action. The National Security Commission on Emerging Biotechnology launched in 2022 to figure out ways to keep the US a leader in the industry. Last spring, it raised the alarm and said the US risks falling behind, laying out a number of policy recommendations to stop the slide.
您已阅读52%（731字），剩余48%（667字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。